Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P05230

UPID:
FGF1_HUMAN

ALTERNATIVE NAMES:
Acidic fibroblast growth factor; Endothelial cell growth factor; Heparin-binding growth factor 1

ALTERNATIVE UPACC:
P05230; B2R5T0; D3DQF2; P07502; Q16588

BACKGROUND:
Fibroblast growth factor 1, known for its roles in cell regulation and angiogenesis, functions as a ligand for FGFR1 and integrins. It is essential for cell survival, division, and migration, acting through signaling pathways like MAPK and AKT1. Its ability to bind and activate FGFR1 in the presence of heparin underscores its significance in cellular signaling.

THERAPEUTIC SIGNIFICANCE:
The therapeutic potential of Fibroblast growth factor 1 lies in its fundamental role in cellular processes and angiogenesis. By elucidating its mechanisms, new pathways for treating diseases related to cell growth and vascular development may be discovered, offering innovative therapeutic avenues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.